Physicians Outlined New Treatment for Lymphoma Patients
The EPCORE NHL-1 trial provided data on managing patient care for relapsed or refractory large B-cell lymphoma.
Updated on Sept. 29, 2026 in Cancer
Medical teams have shifted toward outpatient management for patients receiving epcoritamab to treat relapsed or refractory large B-cell lymphoma. The regimen includes a protocol for addressing cytokine release syndrome outside of the hospital setting.
Why it matters
Managing side effects through remote monitoring and at-home steroid plans allows for greater flexibility in care. This approach reduces the burden of routine hospitalization for patients undergoing intensive cancer treatment.
The EPCORE NHL-1 trial studied the subcutaneous administration of epcoritamab in a cohort that included participants with prior CAR T-cell therapy and double-hit disease. Researchers documented common incidents of cytokine release syndrome alongside infrequent reports of immune effector cell-associated neurotoxicity syndrome.
The players
EPCORE NHL-1
This clinical trial investigated the use of subcutaneous epcoritamab for treating patients with large B-cell lymphoma.
The details
Physicians now utilize risk-based admission criteria rather than requiring routine hospitalization for the first full dose of the drug. Patients are managed through remote monitoring programs and prophylactic use of dexamethasone or prednisone to mitigate side effects like cytokine release syndrome.
Timeline
September 29, 2026: Findings were published regarding the trial protocols.
The Big Picture
This development follows the protocols established by the EPCORE NHL-1 clinical trial. It represents a maturation of treatment delivery, moving from strictly hospital-based clinical oversight to more flexible outpatient management models.
Patients may find increased accessibility to treatment through the shift toward outpatient steroid and hydration management plans. This transition reduces time spent in inpatient facilities for those undergoing therapy for relapsed or refractory lymphoma.
The takeaway
The move toward outpatient care highlights a growing trend in oncology to prioritize patient quality of life while maintaining clinical safety. Patients and caregivers should discuss specific monitoring requirements with their healthcare providers to ensure compliance with at-home safety protocols.
Further reading
For more information on the latest research and advancements in oncology, visit our Cancer section.
